Good neys but how will astm solve the following dillemma about randomized trials:
"The future [of this therapy] is good," Dr. Jimenez reported. However, did state that more trials are needed. "This is a prospective, observational, case-control [trial], but not a randomized, prospective clinical trial," he said, noting that the latter would yield more powerful data, but that clinical reality makes it difficult. "By definition, one group doesn't get the treatment. A patient with a recalcitrant nonunion typically will not sign up for a trial if they have a 50% chance of not even getting the treatment," he said.